Navigation Links
Pharmos Corporation Reports 2008 Second Quarter Results
Date:8/7/2008

ISELIN, N.J., Aug. 7 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS) today reported results for the second quarter ended June 30, 2008. The Company recorded a net loss of $2.7 million, or $0.10 per share, for the second quarter 2008 compared to a net loss of $4.6 million, or $0.18 per share, in the second quarter 2007. Cash and cash equivalents totaled $9.0 million at June 30, 2008.

The decrease in net loss for the second quarter 2008 is due primarily to a 46% decrease in operating expenses to $2.6 million from $4.9 million in the second quarter 2007. The decline in operating expenses resulted from a 41% decrease in gross research and development expenses to $2.1 million compared to $3.7 million in the second quarter 2007. Also general and administrative expenses decreased 66% to $0.5 million from $1.3 million in the second quarter 2007.

During the second quarter, the Company advanced a Phase IIb trial of its lead compound, dextofisopam, in female IBS patients. The Phase IIb trial is expected to enroll approximately 480 patients in about 70 sites in the United States. Costs of $1,470,000 were incurred during the quarter in connection with the trial, comprising CRO-related activities and patient recruitment costs. During the second quarter, the Company engaged a second CRO to identify and manage additional sites. As the Company is currently behind its planned enrollment schedule, additional expenses were incurred in conducting a centralized advertising campaign to enhance patient enrollment. Dextofisopam was one of the compounds the Company obtained through the acquisition of Vela Pharmaceuticals Inc which closed in October 2006. The continued development of this compound through late-stage clinical testing will
'/>"/>

SOURCE Pharmos Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmos Corporation to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
2. Pharmos Corporation Reports 2008 First Quarter Results
3. Pharmos Corporation Completes Initial Closing of Private Placement
4. Pharmos Corporation Announces Board and Management Changes
5. Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
6. Pharmos Corporation to Present at the 2007 RBC Capital Markets Healthcare Conference
7. Pharmos Corporation Reports 2007 Third Quarter Results
8. Pharmos Issues Letter to Shareholders
9. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
10. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target
11. PolyOne Corporation Announces an Exclusive License Agreement with Battelle for Bio-Plasticizer Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Controlled Substance Compliance ... which helps companies check the legal requirements around using ... to China. , As their international operations expand ... adopting software solutions built as a result of the ...
(Date:1/22/2015)... 22, 2015 Diagenode, Inc., a ... the Bioruptor® and complete solutions for epigenetics research, ... immunoprecipitation, alleviating the need for manual processing. The ... for ChIP of histones or transcription factors and ...
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015   ... company, and Sequenom, Inc. (NASDAQ: SQNM ... a development agreement for next generation noninvasive prenatal ... Cypher,s genome interpretation technology, called Mantis™, to advance ...
(Date:1/22/2015)... , Jan. 22, 2015   GenoSpace , a precision medicine ... to enable the broad use of genomic, imaging and other ... appointment of Michelle Munson , CEO of Aspera, an ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 "We ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4GenoSpace Expands Board with Appointment of Michelle Munson 2
... is pleased to announce that it has been selected by ... United Kingdom in the prestigious 2011 awards programme. Trimega beat ... Country Representatives and will now compete for a coveted Ruban ... Trimega,s pioneering use of dual testing of hair to determine ...
... College Park, Md. (May 6, 2011) A bold new ... silicon and may boost their efficiency is the ... and the Institute of Physics, photovoltaic group at the Academy ... for low-cost, high-yield industrial production of solar panels from abundant ...
... America, Inc . (OTC BB: CBAI, CBAID) announced today that the ... its shareholders voting in a recent proxy vote,  is the opening ... one for one hundred reverse split reduces the number of shares ... "D" will be placed on the ticker symbol for 20 business ...
Cached Biology Technology:Trimega Laboratories Honoured to Represent UK at the European Business Awards 2Trimega Laboratories Honoured to Represent UK at the European Business Awards 3'Swiss cheese' design enables thin film silicon solar cells with potential for higher efficiencies 2
(Date:12/19/2014)... 2014   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ...
(Date:12/17/2014)... Dec. 16, 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this market is ... Chemical sensors help in recording of patient data for ...
(Date:12/11/2014)... Dec. 10, 2014  That blood pressure plays a role in ... – the medical term for high blood pressure – was ... the inflatable cuff that,s used in measuring blood pressure was ... nothing new about hypertension, its triggers and its effects. In ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... German . , It is currently estimated that ... those reserves where extraction is cost-effective will only flow for ... Institute for Coal Research and at the Max Planck Institute ... worthwhile to tap into previously unused resources. They have developed ...
... concept of altruism has long been debated in philosophical ... debate. From the perspective of natural selection, altruism ... likelihood of a relative,s survival and reproduction increases the ... Social behavior, kin recognition, and altruism are well known ...
... with colleagues in Sweden and abroad, have identified an entirely ... inhibits formation of new blood vessels. Inhibiting the formation of ... cancer treatment. The study is published in the November issue ... the formation of new blood vessels, is strictly regulated by ...
Cached Biology News:Energy-saving powder 2Energy-saving powder 3Can a plant be altruistic? 2New mechanism explains how the body prevents formation of blood vessels 2
Immunogen: Synthetic peptide: S(399) P W S E L E F Q F P D D K D P V W E F(418) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Human ABCG2 MAb (Clone 5D3)...
Borosilicate Glass. Certified for use with the Beacon 2000 Systems, 1,000 tubes/case...
Whole blood is collected from healthy guinea pigs of either sex from US source which are free of visible diseases at time of blood collection. Hemolytic titer: CH50 = 435 units...
Biology Products: